| 101121-2 |
Candida albicans+tropicalis DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida albicans and tropicalis DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101121-2 |
|
Probe.amp.tar |
|
|
Observation |
|
|
|
0 |
C albicans+tropicalis DNA Bld Ql NAA probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; C albicans; C albicans + tropicalis DNA; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m005; m5; Microbiology; Monilia; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; Thrush; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101122-0 |
Mephobarbital |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Mephobarbital [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
mcg/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101122-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Mephobarbital Bld Cfm-mCnc |
|
|
|
N |
|
Barbiturate; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Mebaral; Methylphenobarbital; Phenitone; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 101123-8 |
Bacterial carbapenem resistance blaIMI gene |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Bacterial carbapenem resistance blaIMI gene [Presence] by Molecular method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
101123-8 |
|
Molgen |
|
|
Both |
|
|
|
0 |
blaIMI Islt/Spm Ql |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; Bact; CPR; Islt; Islt/Spm; Isol; Molecular genetics; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; Screen; Spec |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101124-6 |
Bacterial carbapenem resistance blaIMI+blaNMC genes |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Bacterial carbapenem resistance blaIMI+blaNMC genes [Presence] by Molecular method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
101124-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
blaIMI+blaNMC genes Islt/Spm Ql |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; Bact; CPR; Islt; Islt/Spm; Isol; Molecular genetics; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; Screen; Spec |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101125-3 |
Bacterial carbapenem resistance blaOXA-235-like gene |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Bacterial carbapenem resistance blaOXA-235-like gene [Presence] by Molecular method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
101125-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
blaOXA-235-like gene Islt/Spm Ql |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; Bact; CPR; Islt; Islt/Spm; Isol; Molecular genetics; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; Screen; Spec |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101126-1 |
Bacterial carbapenem resistance blaOXA-24+blaOXA-40 gene |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Bacterial carbapenem resistance blaOXA-24+blaOXA-40 gene [Presence] by Molecular method |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
101126-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
blaOXA-24+blaOXA-40 Islt/Spm Ql |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; Bact; CPR; Islt; Islt/Spm; Isol; Molecular genetics; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; Screen; Spec |
2.78 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101127-9 |
Bacterial carbapenem resistance blaSIM gene |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Bacterial carbapenem resistance blaSIM gene [Presence] by Molecular method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
101127-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
blaSIM Islt/Spm Ql |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; Bact; CPR; Islt; Islt/Spm; Isol; Molecular genetics; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; Screen; Spec |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101128-7 |
Theoretical limit of detection |
Num |
XXX |
Pt |
Qn |
Calculated |
|
ACTIVE |
Theoretical limit of detection [#] in Specimen by calculation |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
MISC |
|
101128-7 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Theoretical limit of detection Spec Calc |
|
|
|
N |
|
Calc; Calculation; Cnt; Count; Misc; Miscellaneous; Number; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.75 |
2.74 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 101129-5 |
Assay Sensitivity |
Num |
Laboratory device |
Pt |
Qn |
|
|
ACTIVE |
Laboratory device Assay Sensitivity |
|
ADD |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
DEVICES |
|
101129-5 |
|
|
|
|
Observation |
|
|
|
0 |
Lab Device |
|
|
|
N |
|
Cnt; Count; Lab Device; Number; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.74 |
2.74 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 10113-9 |
ST wave displacement.end.lead V2 |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
ST wave end displacement in lead V2 |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10113-9 |
|
EKG |
|
|
Observation |
|
|
|
0 |
ST wave ED L-V2 |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave ED L-V2; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101130-3 |
Mast cells/Cells |
NFr |
Bone mar |
Pt |
Qn |
Flow cytometry |
|
ACTIVE |
Mast cells/cells in Bone marrow by Flow cytometry (FC) |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
101130-3 |
|
Flow cytometry |
|
|
Observation |
|
|
|
0 |
Masts NFr Mar FC |
|
|
|
N |
|
BM; BON; Bone marrow; Cell; Cellularity; Dynamic; FC; HEMATOLOGY/CELL COUNTS; MAR; Marrow (bone); Masts; minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.79 |
2.74 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 101131-1 |
B-cell precursors |
NFr |
Bone mar |
Pt |
Qn |
Flow cytometry |
|
ACTIVE |
B-cell precursors in Bone marrow by Flow cytometry (FC) |
|
MAJ |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
101131-1 |
|
Flow cytometry |
|
|
Both |
|
|
|
0 |
B-cell precursors NFr Mar FC |
|
|
|
N |
|
B Cell; B-ALL; B-cell acute lymphoblastic leukemia; BCELLS; BM; BON; Bone marrow; Dynamic; FC; HEMATOLOGY/CELL COUNTS; MAR; Marrow (bone); minimal angle of resolution; Minimum angle of resolution; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.81 |
2.74 |
|
|
|
|
|
|
|
% |
|
|
Release 2.81: SYSTEM: Adjusted system part to Bone mar from Bone marrow; |
0 |
| 101132-9 |
Glucose post XXX challenge panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Glucose post XXX challenge panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101132-9 |
|
|
|
|
Order |
|
|
|
0 |
Glucose post XXX challenge pnl SerPl |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101133-7 |
Organ &or tissue donation consent |
Find |
{Setting} |
Pt |
Doc |
Patient |
|
TRIAL |
Organ AndOr tissue donation consent Document |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
101133-7 |
|
Patient |
|
|
Both |
|
|
|
0 |
Organ AndOr tissue donation consent |
|
|
|
N |
|
DOC.ONT; Document; Finding; Findings; Form; Point in time; Random |
2.74 |
2.74 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 101134-5 |
Appointment reminder |
Find |
{Setting} |
Pt |
Doc |
{Role} |
|
TRIAL |
Appointment reminder |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
101134-5 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Appointment reminder |
|
|
|
N |
|
DOC.ONT; Document; Finding; Findings; Point in time; Random |
2.77 |
2.74 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 101135-2 |
Discharge Summary Note |
Find |
Ambulance |
Pt |
Doc |
{Role} |
|
TRIAL |
Ambulance Discharge summary |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
101135-2 |
|
{Role} |
|
|
Both |
|
|
|
0 |
Ambulance D/C sum |
|
|
|
N |
|
D/C sum; Disch; Discharge summary; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.74 |
2.74 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 101136-0 |
End of treatment letter |
Find |
{Setting} |
Pt |
Doc |
Radiation oncology |
|
TRIAL |
Radiation oncology End of treatment letter |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
101136-0 |
|
Radiation oncology |
|
|
Both |
|
|
|
0 |
Radiation Onc End of treatment letter |
|
|
|
N |
|
Cancer; DOC.ONT; Document; Finding; Findings; Point in time; Random; Tx |
2.74 |
2.74 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 101137-8 |
MNS29 |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
MNS29 [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
101137-8 |
|
|
|
|
Observation |
|
|
|
0 |
MNS29 SerPl Ql |
|
|
|
N |
|
BLOOD BANK; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101138-6 |
ER super little a Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
ER^a Ab [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
101138-6 |
|
|
|
|
Observation |
|
|
|
0 |
ER^a Ab SerPl Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; ER^a; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101139-4 |
H little ro Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Hro Ab [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
101139-4 |
|
|
|
|
Observation |
|
|
|
0 |
Hro Ab SerPl Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; Hro; Hro Ab; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 10114-7 |
ST wave displacement.end.lead V3 |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
ST wave end displacement in lead V3 |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10114-7 |
|
EKG |
|
|
Observation |
|
|
|
0 |
ST wave ED L-V3 |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave ED L-V3; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101140-2 |
Salmonella sp Ag |
PrThr |
Stool |
Pt |
Ord |
IA.rapid |
|
ACTIVE |
Salmonella sp Ag [Presence] in Stool by Rapid immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101140-2 |
|
IA.rapid |
|
|
Both |
|
|
|
0 |
Salmonella Ag Stl Ql IA.rapid |
|
|
|
N |
|
Antigen; Antigens; Bowel movement; EIA; ELFA; ELISA; Enzyme immunoassay; Faecal; Faeces; Fecal; Feces; IAA; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Sal; Salmonel; Screen; species; spp; Stl; Stool = Fecal; SUDS |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101141-0 |
NAT2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
NAT2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
101141-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
NAT2 Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Finding; Findings; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Mut; Mut Anl; Mutations; N-Acetyltransferase 2; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101142-8 |
NAT2 gene allele |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
NAT2 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
101142-8 |
|
Molgen |
|
|
Both |
|
|
|
0 |
NAT2 gene allele Geno Bld/T |
|
|
|
N |
|
Blood; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101143-6 |
NAT2 gene product metabolic activity interpretation |
Imp |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
NAT2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
101143-6 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
NAT2 gene prod met activ imp Bld/T-Imp |
|
|
|
N |
|
Activ; Actvty; Blood; Drug metabolism; Gene prod met act imp; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Movements; NAT2 gene prod met activ imp; Ordinal; PCR; Phenotype; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |